LGND News and Press, Ligand Pharmaceuticals Incorporated

2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...

2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...

2024-07-29 14:43:00 ET Summary Ligand Pharmaceuticals has seen over a 50% increase in share value since its Q1 earnings report. Recent positive developments include new deals, regulatory successes, and raising 2024 guidance. A new deal of close to $200 million with Agenus and ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...

2024-07-23 10:38:53 ET More on the markets Playing Real-Life Monopoly With Blackstone Nasdaq, S&P, Dow are muted as investors brace for key tech earnings Barclays ups S&P year-end target to 5,600, stating the recent selloff looks contained S&P...

2024-07-17 07:16:11 ET More on Johnson & Johnson Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality Johnson & Johnson: Remaining A Buy Despite Remaining Risks Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching...

2024-07-09 10:30:11 ET Craig-Hallum analyst issues BUY recommendation for LGND on July 9, 2024 08:42AM ET. The previous analyst recommendation was Buy. LGND was trading at $86.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...

2024-07-09 10:00:05 ET Matt Hewitt from Craig-Hallum issued a price target of $140.00 for LGND on 2024-07-09 08:42:00. The adjusted price target was set to $140.00. At the time of the announcement, LGND was trading at $86.88. The overall price target consensus is at $117...

2024-07-08 07:17:53 ET More on Ligand Pharmaceuticals Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio Agenus gains after updating early-stage cancer drug data Ligand Pharmaceuticals Non-GAAP EPS of $1.20 beats by $0.37, revenue of $30....

Acquisition provides Ligand with the royalty rights to QARZIBA®, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the b...